映恩生物DUALITYBIO
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
DualityBio Expands Global Strategic Partnership with BioNTech to Accelerate Development of a Third Antibody-Drug Conjugate Therapeutics for Solid Tumors 2023-08-07 18:00
DualityBio Announces DB-1303 Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the Treatment of Advanced, Recurrent or Metastatic Endometrial Carcinoma with HER2 Overexpression 2023-01-20 18:00
Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo 2023-01-05 09:00
Duality announced the appointment of Dr. Pasi A. Jänne as Member of SAB 2022-12-15 21:00
Duality announced the appointment of Dr. Yver as Chairman of SAB 2022-10-03 22:00
Duality Biologics Completed $90 Million Series B Financing 2021-05-20 08:00
1